News
Partner news
VantAI Announces Multi-Year Protein Degrader Discovery Collaboration with Janssen
Read full storyPartner news
Bioasis Enters Into Research Collaboration With Janssen
Read full storyRondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors
Read full storyBiocom conference charts prospects for life sciences industry amid stock market volatility
Read full storyPartner news
Remix Therapeutics Enters Collaboration with Janssen to Advance Small Molecule Therapeutics Using REMaster Drug Discovery Platform to Modulate RNA Processing
Read full storyPartner news
VerImmune Inc Announces Research Collaboration with Janssen to Leverage its Unique Immuno-oncology Therapeutic Platform
Read full storyPartner news
Mersana Therapeutics Announces Research Collaboration and License Agreement with Janssen to Advance Novel Antibody-Drug Conjugates
Read full storyCRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
Read full storyPartner news
Navitor Pharmaceuticals Announces Janssen Has Acquired Anakuria Therapeutics, Inc.
Read full storyIterative Scopes Enters Collaboration to Advance AI and Computer Vision Technologies for Accelerating IBD Clinical Trials
Read full storyImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Read full storyIterative Scopes Announces $150 Million Series B to Advance AI-Driven Precision Medicine for Gastroenterology
Read full storyPartner news
Leyden Labs Licenses Pan-Influenza Antibody from Janssen
Read full storyPartner news